Don Schneider, Piper Sandler deputy head of U.S. policy, joins CNBC's 'The Exchange' to discuss portfolio positioning ahead ...

Fintel reports that on November 8, 2024, Piper Sandler upgraded their outlook for Upstart Holdings (NasdaqGS:UPST) from ...

Piper Sandler last night upgraded Upstart (UPST) to Overweight from Neutral with a price target of $85, up from $31. The company will benefit ...

SolarEdge Technologies rebounds after Trump administration fears, but Q3 loss and forecasted revenue decline raise concerns.

Piper Sandler raised the firm’s price target on ACV Auctions (ACVA) to $18 from $16 and keeps a Neutral rating on the shares following ...

Expectations for President-elect Donald Trump to roll out expansionary fiscal policies and extend U.S. economic ...

Piper Sandler raises Fastly target to $8; keeps Neutral rating. Fastly's Q3 EPS beats estimates, revenue slightly misses ...

Celanese downgraded at Piper Sandler, citing uncertain business environment and financial strain ahead with a precarious condition of the balance sheet.

Piper Sandler Companies Stock Up 0.0 % Shares of PIPR stock opened at $283.66 on Monday. The company has a fifty day moving average price of $289.93. The stock has a market cap of $5.02 billion, a ...

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Piper Sandler Companies (NYSE: PIPR), a leading investment bank, and BC Partners Credit, the $8 billion credit arm of international investment firm BC ...

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for ...

Such findings raised questions about the added benefit of masofaniten, leading ESSA to abandon the drug’s development. In light of these results, Piper Sandler removed any projected value for ...